These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25010056)

  • 1. Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort.
    Julian-Reynier C; Resseguier N; Bouhnik AD; Eisinger F; Lasset C; Fourme E; Noguès C
    Genet Med; 2015 Feb; 17(2):117-24. PubMed ID: 25010056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
    Maheu C; Bouhnik AD; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Berthet P; Fricker JP; Caron O; Luporsi E; Gladieff L; Julian-Reynier C
    Psychooncology; 2014 Apr; 23(4):420-7. PubMed ID: 24127257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.
    Eisinger F; Fabre R; Lasset C; Stoppa-Lyonnet D; Julian-Reynier C; Nogues C
    Eur J Hum Genet; 2012 Sep; 20(9):981-3. PubMed ID: 22378286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disclosure of research results: a randomized study on GENEPSO-PS cohort participants.
    Mancini J; Le Cozannet E; Bouhnik AD; Resseguier N; Lasset C; Mouret-Fourme E; Noguès C; Julian-Reynier C
    Health Expect; 2016 Oct; 19(5):1023-35. PubMed ID: 26205609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parental disclosure of positive
    Troïan J; Apostolidis T; Touzani R; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Berthet P; Julian-Reynier C; Mancini J; Noguès C; Bouhnik AD
    Psychol Health Med; 2020 Jul; 25(6):756-766. PubMed ID: 31505944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of BRCA1/2 mutation on young women's 5-year parenthood rates: a prospective comparative study (GENEPSO-PS cohort).
    Mancini J; Mouret-Fourme E; Noguès C; Julian-Reynier C
    Fam Cancer; 2015 Jun; 14(2):273-9. PubMed ID: 25550141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.
    Dorval M; Noguès C; Berthet P; Chiquette J; Gauthier-Villars M; Lasset C; Picard C; Plante M; ; ; Simard J; Julian-Reynier C
    Eur J Hum Genet; 2011 May; 19(5):494-9. PubMed ID: 21248744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation of the disclosure process and support needs of BRCA1 and BRCA2 carriers.
    Segal J; Esplen MJ; Toner B; Baedorf S; Narod S; Butler K
    Am J Med Genet A; 2004 Mar; 125A(3):267-72. PubMed ID: 14994235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M; Gauthier G; Maunsell E; Dugas MJ; Rouleau I; Chiquette J; Plante M; Laframboise R; Gaudet M; Bridge PJ; Simard J
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.
    Lerman C; Hughes C; Lemon SJ; Main D; Snyder C; Durham C; Narod S; Lynch HT
    J Clin Oncol; 1998 May; 16(5):1650-4. PubMed ID: 9586874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
    Rouleau I; Chiquette J; Plante M; Simard J; Dorval M
    J Obstet Gynaecol Can; 2004 Dec; 26(12):1059-66. PubMed ID: 15607041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO).
    Lecarpentier J; Noguès C; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Caron O; Fricker JP; Gladieff L; Faivre L; Sobol H; Gesta P; Frenay M; Luporsi E; Coupier I; ; Lidereau R; Andrieu N
    Breast Cancer Res Treat; 2011 Dec; 130(3):927-38. PubMed ID: 21761160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
    Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.
    Peshkin BN; Schwartz MD; Isaacs C; Hughes C; Main D; Lerman C
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1115-8. PubMed ID: 12376518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer.
    Conley CC; Ketcher D; Reblin M; Kasting ML; Cragun D; Kim J; Ashing KT; Knott CL; Hughes-Halbert C; Pal T; Vadaparampil ST
    J Genet Couns; 2020 Jun; 29(3):410-422. PubMed ID: 31912597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
    Wagner Costalas J; Itzen M; Malick J; Babb JS; Bove B; Godwin AK; Daly MB
    Am J Med Genet C Semin Med Genet; 2003 May; 119C(1):11-8. PubMed ID: 12704633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.